Related Experiment Videos
Treatment of acute ischemic stroke: recent progress
Norio Tanahashi1, Yasuo Fukuuchi
1Department of Neurology, School of Medicine, Keio University, Tokyo.
Internal Medicine (Tokyo, Japan)
|June 13, 2002
Summary
Current acute ischemic stroke treatments include intravenous thrombolysis and intra-arterial thrombolysis. New therapies like argatroban and edaravone are being investigated, with future treatments potentially combining thrombolytic and neuroprotective drugs.
Area of Science:
- Neurology
- Pharmacology
Background:
- Intravenous thrombolysis with tissue plasminogen activator is the primary treatment for acute ischemic stroke within 3 hours.
- Intra-arterial prourokinase is an option for middle cerebral artery occlusions within 6 hours.
- Heparin's efficacy is unproven, while aspirin offers limited benefits for acute stroke.
Purpose of the Study:
- To evaluate the safety and efficacy of argatroban, a selective thrombin inhibitor, in acute ischemic stroke patients.
- To explore the potential of neuroprotective agents in stroke treatment.
- To investigate future combination therapies for acute ischemic stroke.
Main Methods:
- A randomized, placebo-controlled trial for argatroban in acute ischemic stroke patients.
- Review of existing clinical trial data for thrombolytic and neuroprotective drugs.
- Analysis of treatment efficacy based on time of administration and drug class.
Main Results:
- Tissue plasminogen activator is effective within 3 hours for IV thrombolysis.
- Prourokinase shows promise for intra-arterial treatment within 6 hours.
- Edaravone, a free radical scavenger, is approved in Japan for acute ischemic stroke.
Conclusions:
- Thrombolytic therapies remain crucial for acute ischemic stroke management.
- Ongoing research explores novel anticoagulants like argatroban.
- Future therapeutic strategies will likely involve combined thrombolytic and neuroprotective approaches.